Monomethyl auristatin E (MMAE)

Catalog No.S7721 Synonyms: SGD-1010

For research use only.

Monomethyl auristatin E (MMAE, SGD-1010) is a synthetic antineoplastic agent, which is linked to a monoclonal antibody (MAB). It is also a microtubule-disrupting agent .

Monomethyl auristatin E (MMAE) Chemical Structure

CAS No. 474645-27-7

Selleck's Monomethyl auristatin E (MMAE) has been cited by 5 Publications

Purity & Quality Control

Choose Selective ADC Cytotoxin Inhibitors

Biological Activity

Description Monomethyl auristatin E (MMAE, SGD-1010) is a synthetic antineoplastic agent, which is linked to a monoclonal antibody (MAB). It is also a microtubule-disrupting agent .
In vitro

When coupled to cAC10, MMAE shows selective cytotoxicity in CD30+ cells, and induces G2/M-phase growth arrest and cell death through the induction of apoptosis. [1] When coupled to anti-CD79b antibody, anti–CD79b-vcMMAE has very potent and broad activity across a large panel of NHL cell lines in vitro. [2] When coupled to anti-HER2 antibody, hertuzumab-vc-MMAE can also be effectively internalized and potently kill HER2 over-expressing tumor cells. [3]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
KB Mo\CRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl? M1XjSFQh\GG7cx?= Mme0RY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDoeY1idiCNQjDj[YxteyCjZoTldkA1KGSjeYOgZpkhYFSWIHHzd4F6NCCLQ{WwQVAvODByMUpOwG0> NXjBPJA{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO4OFU4PDNpPkKzPFQ2PzR|PD;hQi=>
BT-12 MXLxTHRUKGG|c3H5 M1TMUJFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCEVD2xNkBk\Wyucx?= M1rKflxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ|OES1O|Q{Lz5{M{i0OVc1OzxxYU6=
A549 MXTBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>? NX3wNmJOPCCmYYnz MUTBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKEF3NEmgZ4VtdHNiYX\0[ZIhPCCmYYnzJIJ6KFiWVDDhd5NigSxiSVO1NF0xNjByMEW5{txO MVS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzh2NUe0N{c,OjN6NEW3OFM9N2F-
non-small cell lung cancer cells MWDDfZRwfG:6aXPpeJkh[XO|YYm= MYKwMlUhfG9iMTDuUS=> NF3lO4Y1KGSjeYO= MlfaR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gco9vNXOvYXzsJINmdGxibIXu[{Bk[W6lZYKgZ4VtdHNiYYSgNE42KHSxIEGgcm0h[W[2ZYKgOEBl[Xm|IHL5JHhVXCCjc4PhfS=> NVe1cXVDRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO4OFU4PDNpPkKzPFQ2PzR|PD;hQi=>
A673 MWTxTHRUKGG|c3H5 MXTxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW|IH\vdkBlenWpIILldJVzeG:|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhSTZ5MzDj[Yxtew>? MYm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTR|MUi1PEc,OjV2M{G4OVg9N2F-
MDA-MB-361 MWHDfZRwfG:6aXPpeJkh[XO|YYm= Mmj2R5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gUWRCNU2ELUO2NUBk\WyuczDhd5Nme3OnZDDhd{Bk\WyuII\pZYJqdGm2eTDpcoN2[mG2ZXSg[o9z\SB2IHThfZMh[nliTWTTJIF{e2G7LDDHTVUxRTBwMECwOFnPxE1? Mn;EQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV2M{G4OVgoRjJ3NEOxPFU5RC:jPh?=
NCI-N87 MULDfZRwfG:6aXPpeJkh[XO|YYm= M37hc2N6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJG5EUS2QOEegZ4VtdHNiYYPz[ZN{\WRiYYOgZ4VtdCC4aXHibYxqfHliaX7jeYJifGWmIH\vdoUhPCCmYYnzJIJ6KE2WUzDhd5NigSxiR1m1NF0xNjByMEW0{txO MVm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTR|MUi1PEc,OjV2M{G4OVg9N2F-
OHS-50 NH\ze5pyUFSVIHHzd4F6 NHzM[2JyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiT1jTMVUxKGOnbHzz MnPFQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh{MUGyO|coRjJ6MkGxNlc4RC:jPh?=
DU145 MkHOS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NWexXGQ3PDhiaILz NYjtS203T3Kxd4ToJIlvcGmkaYTpc44hd2ZiaIXtZY4hTFVzNEWgZ4VtdHNiaX7jeYJifGWmIH\vdkA1QCCqcoOgZpkhVVSWIHHzd4F6NCCJSUWwQVAvODByNEG4{txO M2rLS|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6MkGxNlc4Lz5{OEKxNVI4PzxxYU6=
SF268 MXXHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NYL3e4pFPDhiaILz MXzHdo94fGhiaX7obYJqfGmxbjDv[kBpfW2jbjDTSlI3QCClZXzsd{BqdmO3YnH0[YQh\m:{IES4JIhzeyCkeTDNWHQh[XO|YYmsJGdKPTB;MD6wNFA1OzMQvF2= MWK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDJzMUK3O{c,Ojh{MUGyO|c9N2F-
KM20L2 NHjx[mpIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MXm0PEBpenN? NIDkTVNIem:5dHigbY5pcWKrdHnvckBw\iCqdX3hckBMVTJyTEKgZ4VtdHNiaX7jeYJifGWmIH\vdkA1QCCqcoOgZpkhVVSWIHHzd4F6NCCJSUWwQVAvODByNUm5{txO M{WzblxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6MkGxNlc4Lz5{OEKxNVI4PzxxYU6=
NCI-H460 NXTlNIRCT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NEHBfpY1QCCqcoO= MYDHdo94fGhiaX7obYJqfGmxbjDv[kBpfW2jbjDOR2kuUDR4MDDj[YxteyCrbnP1ZoF1\WRiZn;yJFQ5KGi{czDifUBOXFRiYYPzZZktKEeLNUC9NE4xODB4OEROwG0> NVHHVI1SRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkiyNVEzPzdpPkK4NlEyOjd5PD;hQi=>
HCT116 MoeySpVv[3Srb36gZZN{[Xl? M4jO[lAvPSCvTR?= MWCyOEBpenN? NVnaPZIxTW[oZXP0JI9vKG2rdH;jbI9v\HKrYXygdoV{eGm{YYTpc44hcW5iaIXtZY4hUEOWMUG2JINmdGy|IHX4dJJme3OrbnegZ4Fz[m:waXOgZY5pgWS{YYPlJFkh[XO|ZYPz[YQh[XNicnXkeYN1cW:wIHnuJI95gWenbjDjc45{fW2ydHnvckBz[XSnIHH0JFAvPSCvTTDh[pRmeiB{NDDodpMhfW6mZYKgbJlxd3irYzDjc45lcXSrb36gZpkhX2W|dHXyckBjdG:2IHHuZYx6e2m| M1nUfFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6OEm1N|k1Lz5{OEi5OVM6PDxxYU6=
DU145 NInQW2lIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NUnIfVdSPDhiaILz M{X1cmdzd3e2aDDpcohq[mm2aX;uJI9nKGi3bXHuJGRWOTR3IHPlcIx{KGGodHXyJFQ5KGi{czDifUBUWkJiYYPzZZktKEeLNUC9NE4xODB2MUlOwG0> NUPwe2piRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMki4PVU{QTRpPkK4PFk2Ozl2PD;hQi=>
SF268 M4HQR2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NXHES2VFPDhiaILz NGfNfW9Iem:5dHigbY5pcWKrdHnvckBw\iCqdX3hckBUTjJ4ODDj[YxteyCjZoTldkA1QCCqcoOgZpkhW1KEIHHzd4F6NCCJSUWwQVAvODByNEOy{txO M1LkOlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6OEm1N|k1Lz5{OEi5OVM6PDxxYU6=
KM20L2 M361e2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MUO0PEBpenN? MWjHdo94fGhiaX7obYJqfGmxbjDv[kBpfW2jbjDLUVIxVDJiY3XscJMh[W[2ZYKgOFghcHK|IHL5JHNTSiCjc4PhfUwhT0l3ME2wMlAxODV7Od88US=> NE\FSXA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEi5OVM6PCd-Mki4PVU{QTR:L3G+
NCI-H460 MUXHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? M3LqXVQ5KGi{cx?= MX3Hdo94fGhiaX7obYJqfGmxbjDv[kBpfW2jbjDOR2kuUDR4MDDj[YxteyCjZoTldkA1QCCqcoOgZpkhW1KEIHHzd4F6NCCJSUWwQVAvODByNkiz{txO NX;NUHlHRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMki4PVU{QTRpPkK4PFk2Ozl2PD;hQi=>
MCF7 NUC0bJBlT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MY[0PEBpenN? M4DSV2dzd3e2aDDpcohq[mm2aX;uJI9nKGi3bXHuJG1ETjdiY3XscJMh[W[2ZYKgOFghcHK|IHL5JHNTSiCjc4PhfUwhT0l3ME2wMlAxODRyNN88US=> Mn3rQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh7Mk[yOFAoRjJ6OUK2NlQxRC:jPh?=
DU145 NEHxRY9Iem:5dHigbY5pcWKrdHnvckBie3OjeR?= MlLsOFghcHK| MoDjS5Jwf3SqIHnubIljcXSrb36gc4YhcHWvYX6gSHUyPDViY3XscJMh[W[2ZYKgOFghcHK|IHL5JHNTSiCjc4PhfUwhT0l3ME2wMlAxODRzON88US=> NFXEXpQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEmyOlI1OCd-Mki5NlYzPDB:L3G+
SF268 MkLiS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NFrhWnM1QCCqcoO= Mn3qS5Jwf3SqIHnubIljcXSrb36gc4YhcHWvYX6gV2YzPjhiY3XscJMh[W[2ZYKgOFghcHK|IHL5JHNTSiCjc4PhfUwhT0l3ME2wMlAxODR|Mt88US=> M3XiZ|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6OUK2NlQxLz5{OEmyOlI1ODxxYU6=
KM20L2 NEH5V3pIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NFj2UZo1QCCqcoO= M2H6e2dzd3e2aDDpcohq[mm2aX;uJI9nKGi3bXHuJGtOOjCOMjDj[YxteyCjZoTldkA1QCCqcoOgZpkhW1KEIHHzd4F6NCCJSUWwQVAvODByNUm5{txO M1S2elxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6OUK2NlQxLz5{OEmyOlI1ODxxYU6=
NCI-H460 NFnST2RIem:5dHigbY5pcWKrdHnvckBie3OjeR?= Mo[zOFghcHK| NInX[4xIem:5dHigbY5pcWKrdHnvckBw\iCqdX3hckBPS0lvSES2NEBk\WyuczDh[pRmeiB2ODDodpMh[nliU2LCJIF{e2G7LDDHTVUxRTBwMECwOlg{|ryP NYC1VVd1RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMki5NlYzPDBpPkK4PVI3OjRyPD;hQi=>
DAOY NHH1VGxyUFSVIHHzd4F6 NFjwWXJyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiRFHPXUBk\Wyucx?= NWn4ToFtRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMki5O|I4PTVpPkK4PVczPzV3PD;hQi=>
A549 MX7BcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>? Mn7QO|IhcHK| MoHQRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDoeY1idiCDNUS5JINmdGy|IHHmeIVzKDd{IHjyd{BjgSCPVGOgZZN{[XluIFXDOVA:OC5yMEC1{txO NGrGO5U9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEm3Nlc2PSd-Mki5O|I4PTV:L3G+
SKOV3 Ml2xR5l1d3SxeHnjbZR6KGG|c3H5 MmnUNkBl[Xm| NHHBSXNEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBUU0:YMzDj[YxteyCjZoTldkAzKGSjeYOgZpkh[2WubDD0bZRmeiB7NjDhdZVmd3W|IH;u[UB{d2y3dHnvckBj[XOnZDDhd5NigSxiSVO1NF0xNjByME[2{txO M3jLPFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEW0O|A{Lz5{OUS1OFcxOzxxYU6=
A549 NILTbIREgXSxdH;4bYNqfHliYYPzZZk> MWKyJIRigXN? NXHuSFRiS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hSTV2OTDj[YxteyCjZoTldkAzKGSjeYOgZpkh[2WubDD0bZRmeiB7NjDhdZVmd3W|IH;u[UB{d2y3dHnvckBj[XOnZDDhd5NigSxiSVO1NF0xNjByMUROwG0> M1\NZVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEW0O|A{Lz5{OUS1OFcxOzxxYU6=
L1210 MVHDfZRwfG:6aXPpeJkh[XO|YYm= M4TDUVIh\GG7cx?= NU\1WolGS3m2b4TvfIlkcXS7IHHnZYlve3RibX;1d4UhVDF{MUCgZ4VtdHNiYX\0[ZIhOiCmYYnzJIJ6KGOnbHygeIl1\XJiOU[gZZF2\W:3czDvcoUhe2:udYTpc44h[mG|ZXSgZZN{[XluIFnDOVA:OC5yMEKx{txO NXnXVmFzRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0OVQ4ODNpPkK5OFU1PzB|PD;hQi=>
NCI-H524 MV7DfZRwfG:6aXPpeJkh[XO|YYm= NWn6OnFrOiCqcoO= NXXDS40zS3m2b4TvfIlkcXS7IHnuJIh2dWGwIF7DTU1JPTJ2IHPlcIx{KHC{ZT3pcoN2[mG2ZXSg[o9zKDJiaILzJIZwdGyxd3XkJIJ6KGOxbYDveY5lKHejc3igc5V1KGGwZDDzeYJ{\XG3ZX70cJkhcW6ldXLheIVlKG[xcjC3NEBpenNiYomgR4VtdCCWaYTldkBIdG9iYYPzZZktKEmFNUC9NE4xODN5zszN NFrweGk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9|MEezOVM5PSd-M{C3N|U{QDV:L3G+
In vivo In the Karpas 299 ALCL model, cAC10-vcMMAE (1 mg/kg, i.v.) induces complete, durable tumor regression, while free MMAE (0.36 mg/kg) doesn’t produce detectable antitumor activity. [1] In mouse xenograft models of NHL, anti–CD79b-vcMMAE (7 mg/kg, p.o.) strikingly results in sustained complete tumor remission. [2]

Protocol (from reference)

Cell Research:

[1]

  • Cell lines: CD30+ Karpas 299 cells
  • Concentrations: ~1000 ng/mL
  • Incubation Time: 96 h
  • Method:

    Cytotoxicity is measured using Alamar Blue dye reduction assay according to the manufacturer's directions. Briefly, a 40% solution (wt/vol) of Alamar Blue is freshly prepared in complete media just before cultures are added. Ninety-two hours after drug exposure, Alamar Blue solution is added to cells to constitute 10% culture volume. Cells are incubated for 4 hours, and dye reduction is measured on a Fusion HT fluorescent plate reader (Packard Instruments, Meriden, CT).

  • (Only for Reference)

Solubility (25°C)

In vitro

DMSO 100 mg/mL
(139.27 mM)
Water Insoluble
Ethanol '100 mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 717.98
Formula
C39H67N5O7
 
CAS No. 474645-27-7
Storage 3 years -20°C powder
2 years -80°C in solvent
Smiles CCC(C)C(C(CC(=O)N1CCCC1C(C(C)C(=O)NC(C)C(C2=CC=CC=C2)O)OC)OC)N(C)C(=O)C(C(C)C)NC(=O)C(C(C)C)NC

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg g μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO % % Tween 80 % ddH2O
%DMSO %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Interventions Conditions Sponsor/Collaborators Start Date Phases
NCT04879329 Not yet recruiting Drug: Disitamab vedotin Urothelial Carcinoma Seagen Inc.|RemeGen Co. Ltd. March 31 2022 Phase 2
NCT05126719 Recruiting Drug: MRG003 Recurrent or Metastatic Nasopharyngeal Carcinoma Shanghai Miracogen Inc. August 4 2021 Phase 2
NCT05188209 Recruiting Drug: MRG003 Advanced or Metastatic Gastric Cancer|Advanced or Metastatic Gastroesophageal Junction Carcinoma Shanghai Miracogen Inc. May 24 2021 Phase 2
NCT04492488 Recruiting Drug: MRG002 Advanced Solid Tumors|Advanced or Metastatic Gastric Cancer|Advanced or Metastatic Gastroesophageal Junction Cancer Shanghai Miracogen Inc. May 24 2021 Phase 1|Phase 2
NCT04868162 Recruiting Drug: MRG003 Recurrent or Metastatic Squamous Cell Carcinoma of Head and Neck Shanghai Miracogen Inc. April 23 2021 Phase 2
NCT04617314 Recruiting Drug: RC108 Solid Tumor RemeGen Co. Ltd. March 10 2021 Phase 1

(data from https://clinicaltrials.gov, updated on 2022-01-17)

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

Please enter your name.
Please enter your email. Please enter a valid email address.
Please write something to us.
Tags: buy Monomethyl auristatin E (MMAE) | Monomethyl auristatin E (MMAE) supplier | purchase Monomethyl auristatin E (MMAE) | Monomethyl auristatin E (MMAE) cost | Monomethyl auristatin E (MMAE) manufacturer | order Monomethyl auristatin E (MMAE) | Monomethyl auristatin E (MMAE) distributor